The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

An RSV vaccine approved for use in older adults could help protect people as young as 50 who have certain underlying medical conditions and are at increased risk from the respiratory virus ...

Recently, GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This ...

GSK's Arexvy became the first FDA-approved RSV vaccine in May 2023. At the time, it was only cleared for use on adults aged 60 and older, who are more vulnerable to severe cases of RSV lower ...

GSK has revealed trial results that show the effectiveness of its RSV vaccine Arexvy in adults aged 50-59. The data could allow for a label expansion.

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...

The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker ...

GSK’s push to expand the label for its blockbuster respiratory syncytial virus (RSV) vaccine will strengthen its position against Pfizer, according to analysts at GlobalData. Late last month ...

Putting this figure into perspective is that analysts forecast GSK to generate 11,693 million pounds from its vaccines in total for the same year, thus affording its RSV OA vaccine a forecasted 10 ...

Recently, GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement ...